APA (7th ed.) Citation

W, L., WB, W., S, K., Jr, G. L., DL, V., & M, L. (2022). Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. PharmacoEconomics, 40(6), 623. https://doi.org/10.1007/s40273-022-01147-5

Chicago Style (17th ed.) Citation

W, Lee, Wong WB, Kowal S, Garrison LP Jr, Veenstra DL, and Li M. "Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer." PharmacoEconomics 40, no. 6 (2022): 623. https://doi.org/10.1007/s40273-022-01147-5.

MLA (9th ed.) Citation

W, Lee, et al. "Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer." PharmacoEconomics, vol. 40, no. 6, 2022, p. 623, https://doi.org/10.1007/s40273-022-01147-5.